Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 16/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.63 |
| ▸ | STAT3 | P40763 | 2/20 | 0.63 |
| ▸ | ALPL | P05186 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840752 | 0.88 | CREBBP (0.74) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840609 | 0.87 | STAT3 (0.74) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840754 | 0.86 | CREBBP (0.56) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840769 | 0.83 | STAT3 (0.74) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840585 | 0.82 | MAPT (0.74) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL12473146 | 0.80 | MAPT (0.85) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840684 | 0.80 | MAPT (0.64) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840580 | 0.80 | CREBBP (0.65) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840614 | 0.79 | MAPT (0.64) | CREBBPMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL15840788 | 0.78 | MAPT (1.00) | CREBBPMAPTALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | CREBBP 1243/4885MAPT 1076/4885ALDH1A1 4348/4885 |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | CREBBP 1749/4885MAPT 3443/4885ALDH1A1 2506/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | CREBBP 1749/4885MAPT 3443/4885ALDH1A1 2506/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | CREBBP 1749/4885MAPT 3443/4885ALDH1A1 2506/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | CREBBP 1749/4885MAPT 3443/4885ALDH1A1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.